Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patiromer JADE Study in Chinese Subjects with Hyperkalaemia
NCT05136664Phase 3Completed
- Sponsor
- CSL Vifor
- Start
- Feb 2022
- Primary completion
- Nov 2025
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in hyperkalemia comparing Patiromer -> Placebo with Patiromer -> Patiromer (2 arms). Primary endpoints: Change from baseline in the serum potassium (sK+) at 4 weeks and Change from Week 4 in sK+ at 8 weeks. Started Feb 2022; status: completed.
02
Drugs
patiromer
03
Conditions
hyperkalemia
Beyond the preview
Go deeper on NCT05136664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05136664.